Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Uric Acid to Albumin Ratio for Predicting Contrast Associated Acute Kidney Injury After Cardiac and Non Cardiac Procedures

28. september 2026 oppdatert av: Maher Nasser Rsof Atia, Assiut University

Predictive Value of the Uric Acid to Albumin Ratio for Contrast Associated Acute Kidney Injury After Cardiac and Non Cardiac Procedures

Contrast-associated acute kidney injury (CA-AKI) is a potential complication that can occur following exposure to iodinated contrast media during diagnostic and interventional procedures, contributing to prolonged hospital stays, increased morbidity, and higher mortality. Although several clinical risk factors are well-recognized, pre-procedural risk stratification remains challenging. The serum uric acid-to-albumin ratio (UAR) has emerged as a composite biomarker reflecting oxidative stress and inflammation that may help identify vulnerable patients prior to contrast exposure.

The primary purpose of this prospective observational cohort study is to evaluate the predictive performance of the pre-procedural uric acid-to-albumin ratio for the development of contrast-associated acute kidney injury. The study will also compare the predictive value of UAR between patients undergoing cardiac procedures, specifically percutaneous coronary intervention (PCI), and those undergoing non-cardiac contrast procedures.

A total of 100 adult participants will be enrolled across two groups: 50 patients undergoing PCI and 50 patients undergoing non-cardiac contrast procedures. Baseline venous blood samples will be obtained prior to the procedure to measure serum creatinine, uric acid, and albumin levels. Follow-up kidney function tests will be evaluated at 48 and 72 hours post-procedure to detect the development of CA-AKI and assess the diagnostic accuracy of pre-procedural UAR.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Observasjonsmessig

Registrering (Antatt)

100

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

N/A

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adult patients admitted to or evaluated at the Internal Medicine Department and related catheterization and interventional units at Assiut University Hospital who are scheduled to undergo cardiac (percutaneous coronary intervention) or non-cardiac diagnostic and interventional procedures requiring exposure to iodinated contrast media.

Beskrivelse

Inclusion Criteria:

  • Adult patients aged 18 years or older undergoing a cardiac or non-cardiac procedure requiring iodinated contrast media.
  • Cardiac group: patients undergoing percutaneous coronary intervention (PCI).
  • Non-cardiac group: patients undergoing other diagnostic or interventional contrast procedures.
  • Provision of written informed consent prior to enrollment.
  • Available baseline (pre-procedural) serum creatinine, uric acid, and albumin measurements.

Exclusion Criteria:

  • Severe chronic kidney disease or end-stage renal disease on regular maintenance hemodialysis (baseline eGFR < 15 mL/min/1.73 m^2).
  • Exposure to iodinated contrast media within the preceding 7 to 10 days.
  • Acute kidney injury from any cause present at admission or prior to contrast exposure.
  • Active infection, sepsis, or systemic inflammatory response syndrome at the time of enrollment.
  • Known history of gout, current use of urate-lowering therapy, or hematologic malignancy affecting uric acid metabolism.
  • Severe hepatic disease or marked proteinuria affecting serum albumin independently of the study condition.
  • Emergent PCI where baseline laboratory samples could not be obtained prior to contrast exposure.
  • Patient death occurring before the 48 to 72 hour post-procedural serum creatinine evaluation could be performed.
  • Pregnancy.
  • Refusal of informed consent or loss to follow-up prior to outcome assessment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Cardiac Group (PCI)

Adult patients undergoing percutaneous coronary intervention (PCI) requiring exposure to iodinated contrast media. Baseline serum creatinine, uric acid, and albumin are measured pre-procedure, and renal function is monitored at 48 and 72 hours post-procedure to assess the development of contrast-associated acute kidney injury (CA-AKI).

Non-Cardiac Group

Adult patients undergoing non-cardiac diagnostic or interventional procedures requiring exposure to iodinated contrast media. Baseline serum creatinine, uric acid, and albumin are measured pre-procedure, and renal function is monitored at 48 and 72 hours post-procedure to assess the development of contrast-associated acute kidney injury (CA-AKI).

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Contrast-Associated Acute Kidney Injury (CA-AKI)
Tidsramme: 72 hours post-procedure

Defined as an absolute increase in serum creatinine of at least 0.5 mg/dL (44.2 micromol/L) or a relative increase of at least 25% from baseline, evaluated within 72 hours following iodinated contrast media exposure.

72 hours post-procedure

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. november 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

28. september 2026

Først innsendt som oppfylte QC-kriteriene

28. september 2026

Først lagt ut (Faktiske)

2. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere